• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New nonprofit to seek consensus on social media

New nonprofit to seek consensus on social media

June 17, 2011
CenterWatch Staff

Frustrated by FDA inaction on guidance for digital marketing and social media, a host of industry players are banding together to form a nonprofit that can hammer out consensus on a way forward, according to Medical Marketing & Media.

The Digital Health Coalition is being convened by Mark Bard, formerly of Manhattan Research, and boasts some of the drug and digital health industries' biggest names on its advisory board. Among them are representatives from Merck, Roche, AstraZeneca, Lilly, Sanofi and GlaxoSmithKline, Google, Epocrates and HealthCentral, along with agencies Edelman and Digitas Health.

The aim, said Bard, is to get a conversation started.

“A lot of us have ideas about how the industry can evolve,” says Bard. “Let's start that conversation, with Google and Epocrates in the room and the coalition as a facilitator, and then work with DDMAC and from almost a liaison perspective say: ‘Hey, would you like to be a part of this conversation?'”

After a marathon two-day DDMAC public hearing on the topic in 2009, many drug marketers and medical agency execs were hopeful that the FDA would soon issue guidance that might narrow the regulatory gray areas in digital marketing. The agency first delayed and then scotched those hopes, pending further studies, by saying in late March, more or less: Don't hold your breath.

The industry has, to one extent or another, moved on, however cautiously, having accepted that little official clarity is forthcoming. The Digital Health Coalition's position, said Bard, is that it's not the government's job to tell industry how to market its products responsibly through digital channels. Rather, he said, “We fully intend to engage DDMAC and to come up with an industry consensus and say, ‘This is what we think makes sense.'”

The Digital Health Coalition will issue white papers and convene roundtables and webinars looking at three issues: mobile health, social media in health and search. An introductory webinar is scheduled for June 23 at 10 a.m. EST.

 

Enter Content Here

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing